Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and corporate updates announced on November 5, 2026.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and corporate updates announced on November 5, 2026
- Full results and management commentary available in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 collaboration revenue $4.0M, down from $13.4M, reflecting reduced Neurocrine revenue as programs move beyond research
- R&D expense $24.4M, down from $35.9M, while net loss narrowed to $24.7M from $27.9M
- Cash, equivalents and marketable securities $132.1M at September 30, supporting planned operations into Q2 2028
- VY7523 tau-PET efficacy data remains expected in Q4 2026, a major near-term Alzheimer’s valuation catalyst
- VY1706 dosing expected within months, with initial safety data targeted for Q1 2027 and Neurocrine’s NBIB-223 entering Phase 1 soon
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.